116 Hikma PHarmaceuticals Plc annual report 2011 notes to the consolidated financialstatements Continued 6. profit for the year Continued a detailed analysis of the Groups auditors remuneration on a worldwide basis is provided below: 2011 2010 $000 $000 audit of the companys annual accounts 324 367 audit of the companys subsidiaries pursuant to legislation 825 619 Total audit fees 1,149 986 audit related services 463 115 Total audit and audit related fees 1,612 1,101 tax compliance services 135 128 tax advisory services 239 281 other services 1,748 3,159 transaction due diligence services 345 Total non-audit fees 2,122 3,913 Total fees 3,734 5,014 these fees predominantly relate to review procedures in respect of the interim financial information and the opening balance sheet audit of the msi business, recently acquired from Baxter Healthcare and Promopharm.
this also includes prospectus work relating to the Promopharm acquisition.
Other services relate to integration planning performed in the us in respect of the msi acquisition.
further details in respect of this service are set out on page 69. a description of the work of the audit committee is set out in the audit committee report on pages 66 to 69 and includes an explanation of how auditor objectivity and independence is safeguarded when non-audit services are provided by the auditor.
7. staff costs the average monthly number of employees including executive Directors was: 2011 2010 number number production 3,625 3,048 sales and marketing 1,699 1,625 research and development 239 186 general and administrative 602 537 6,165 5,396 2011 2010 $000 $000 Their aggregate remuneration comprised: wages, salaries and bonuses 175,627 121,027 social security costs 15,051 10,122 post-employment benefits 3,559 2,433 end of service indemnity 2,934 2,756 share-based payments 7,507 4,473 car and housing allowance 13,483 12,651 other costs and employee benefits 19,678 15,495 237,839 168,957
